Ivo Francischetti and Colleagues on Glycoprotein VI Contributing to Platelet Activation in HIT
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn:
”Glycoprotein VI is a receptor for the PF4/anti-PF4 IgG complex and contributes to platelet activation in heparin-induced thrombocytopenia (HIT)
By Ivo Francischetti, Kathryn Dane, Ed Galgo, Michael B. Streiff, and John F. Andersen
Heparin-induced thrombocytopenia (HIT) involves platelet activation by PF4/anti-PF4 complexes.
This study identifies glycoprotein VI (GPVI) as a receptor for these complexes, enhancing PF4 binding (Kd ≈ 30–100 nM) and platelet aggregation via FcγRIIA.
GPVI blockade (anti-GPVI antibodies, ACT017) suppressed activation, while AlphaFold modeling revealed electrostatic interactions between GPVI and PF4/IgG.
These findings position GPVI as a potential therapeutic target in HIT.”
Read the full article in JTH.
Article: Glycoprotein VI is a receptor for the PF4/anti-PF4 IgG complex and contributes to platelet activation in heparin-induced thrombocytopenia (HIT)
Authors: Ivo Francischetti, Kathryn Dane, Ed Galgo, Michael Streiff, John Andersen
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 11, 2025, 09:06Natalia Peres Martinez - Surgical Bleed: Replacing Gut Feeling With Guided Thinking
-
Oct 11, 2025, 09:00Muhammad Ali - Hematology In Pakistan: The Silent Revolution In Diagnosis And A Blueprint For Growth
-
Oct 11, 2025, 08:50Robert Zeiser: New Insights and Timeless Lessons in Transplantation
-
Oct 11, 2025, 08:39Mildred Lundgren: These 5 Proposals Are A Clear Road Map for The Future And We Support Them Wholeheartedly
-
Oct 11, 2025, 08:33RPTH Journal: Does Fasting Affect Anticoagulant Therapy? - The Effects Of Fasting During Ramadan
-
Oct 12, 2025, 10:14Hatim Lokhandwala: Landmark HI-PRO Trial Redefines VTE Treatment Guidelines
-
Oct 11, 2025, 18:47Endovascular Today: SYMPHONY-PE Trial and Advances in Pulmonary Embolism Treatment
-
Oct 11, 2025, 08:49Rodrigo Assar: We Are Pushing the Boundaries by Using Computational Approaches
-
Oct 11, 2025, 08:48Deborah Wild: Thrilled to See GeneVentiv Selected for The NIH NHLBI Catalyze Program
-
Oct 11, 2025, 08:34Ivo Francischetti and Colleagues on Glycoprotein VI Contributing to Platelet Activation in HIT
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 7, 2025, 13:06Bobur Kholikov on iFlash Thrombosis Panel – D-Dimer
-
Oct 7, 2025, 03:502025 Nobel Prize: A Milestone for Autoimmunity Research - Awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi
-
Oct 11, 2025, 08:57Jeff June - Seeing The Invisible: How Spatial Biology Is Opening A New Chapter In Stroke Care
-
Oct 11, 2025, 08:11Khaled Musallam: Honored to Be Featured for The 7th Year in A Row in The World’s Top 2% Most-Cited Scientists
-
Oct 11, 2025, 08:07Britta Diebel: This Has Been An Intense, Good Week, Although IPAW Actually Lasts All Year Long
-
Oct 10, 2025, 03:10Marilena Vrana: Plasma-Derived Medicines Are a Clear Example of Why A One-Size-Fits-All Approach Won’t Work
-
Oct 10, 2025, 03:07Nancy Di Salvo: It's IPAW 2025, How Could I Not Take a Moment to Thank Every Single Plasma Donor Out There?